Transvaginal mesh surgery for pelvic organ prolapse-Prolift plus M: a prospective clinical trial

Introduction and hypothesis This study deals with assessment of safety, efficacy, and potential complications of Prolift+M system to correct uterovaginal prolapse. Methods We analyzed a prospective cohort treated with the Gynecare PROLIFT+M mesh system between October 2008 and March 2010. A composite score that included subjective/objective cure and lack of complications was used to assess treatment success. Results One hundred sixty-seven women (age 65.1 +/- 11.2 years, BMI 29.2 +/- 5.8 kg/m(2)) were treated for pelvic organ prolapse using the PROLIFT+M system. Seven anterior Prolift+M, 42 posterior Prolift+ M, and 118 total Prolift+M mesh surgeries were performed in patients with stage II or greater degrees of prolapse. Mean operative time was 122.7 +/- 43.9 min. Mean intraoperative blood loss was 119.4 +/- 125.3 ml. Our composite success score was 72.5% (treatment failures per POP-Q stage 1.4%, perception of bulge 4.4%, erosions 3.6%, pain/dyspareunia 3.7%, incontinence 0.7%, de novo urge urinary incontinence 8.7%, voiding dysfunction 0.6%, recurrent urinary tract infection 2.2%, and anal incontinence 2.2%). Conclusions Prolift+M surgery is safe and effective with minimal postoperative morbidities.